Kornimate/medical-research-clean huggingface dataset:
molecular epidemiology, strains genotyping of multi-drug resistant tuberculosis circulating in central africa region

Conditions: Tuberculosis, Multi Drug Resistant; Strains; Molecular Epidemiology; Multi Drug Resistant Tuberculosis; Central Africa

Summary: multidrug-resistant tuberculosis (mdr-tb) poses a significant challenge in central africa. understanding the molecular epidemiology and genotypic characteristics of mdr-tb strains is crucial for effective control measures. this is highlighted by the emergence of mutations encoding resistance to bed aquiline and quinolones which may impact the roll out of the newly recommended bedaquiline, pretomanid, linezolid and moxifloxacin (bpalm) regimens. it is also worth noting that there is increasing evidence of the significance of tb lineage in the outcome of infection, the approach in the study will provide both information on chains of transmission and lineage.


Eligibility criteria:
inclusion criteria: * all genexpert positive tb patients and participants who provide written informed consent will be screened for the study. participants aged above 8 who can provide sputum will also be screened. * patients enrolled in the tuberculosis epidemiology (tb-epi) study and eligible for mestcar will be enrolled without any additional consent form as the data to be collected for the two studies will be shared and no additional process is needed. exclusion criteria: * samples which do not meet the quality criteria. * samples not enough to perform all of the laboratory process * samples contaminated
a trial of shr0410 injection for the treatment of pain after endoscopic surgery of the lower abdominal

Conditions: Pain

Summary: the study is being conducted to evaluate the efficacy and safety of shr0410 injection for the treatment of pain after endoscopic surgery of the lower abdominal.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide a written informed consent 2. subjects requiring elective general anesthesia endoscopic surgery of the lower abdominal 3. male or female 4. meet the body mass index standard 5. conform to the asa physical status classification exclusion criteria 1. subjects with a history of difficult airway 2. subjects with a history of mental illness 3. subjects with a history of cognitive impairment epilepsy 4. subjects with a history of myocardial infarction or unstable angina pectoris 5. subjects with atrioventricular block or cardiac insufficiency 6. subjects with a history of ischemic stroke or transient ischemic attack 7. subjects with poor blood pressure control after medication 8. subject with a history of substance abuse and drug abuse 9. abnormal values in liver function 10. subjects with an oxygen saturation below 90% on room air 11. allergic to drugs that may be used during the study 12. pregnant or nursing women 13. no birth control during the specified period of time 14. participated in clinical trials of other drugs (received experimental drugs) 15. the investigators determined that other conditions were inappropriate for participation in this clinical trial
microbiological evaluation of the ocular flora before cataract surgery

Conditions: Disorders of the Eye Following Cataract Surgery

Summary: the purpose of the present study is to elucidate the spectrum of ocular flora and their antimicrobial susceptibility profiles in patients undergoing routine cataract surgery.

a conjunctival and palpebral swab will executed at least 14 days before routine cataract surgery. isolates will be identified using standard microbiological protocols. in vitro susceptibility will be determined using a breakpoint minimal inhibitory concentrations. in case of positivity, the swab will be repeated the day of surgery. topical antibiotic may be used in case of positivity at the discretion of the surgeon. descriptive statistics will be calculated.

Eligibility criteria:
inclusion criteria: * patients scheduled for cataract surgery * age \> 18 years * any gender and race * willing to sign informed consent exclusion criteria: * any antibiotics within 3 months * any ocular infection within 3 months

Keywords: cataract prophylaxis susceptibility
natural history of nfai: 10 year follow-up results

Conditions: Adrenal Incidentaloma

Summary: the data on long term natural history of benign nonfunctioning adrenal tumors (nfats) are lacking. the aim is to identify clinical characteristics associated with tumor growth and progression to mild autonomous cortisol excess over time.

after being informed about the study, all patients with nfat given written informed consent will underwent a control visit approximatly 10 years after initial visit at the outpateint clinic at the department of endocrinology, diabetes and metabolic disease, university medical center ljubljana, ljubljana, slovenia. the included patients will be divided in three groups regarding the bmi as follows: bmi \ 30 kg/m2. the investigators will assess clinical, and laboratory parameters and ct findings at the follow up visit and compere them to baseline characteristics.

Eligibility criteria:
inclusion criteria: - patients hospitalized because of nfai between 2005-2012 at the department of endocrinology, diabetes and metabolic disease, university medical center ljubljana, ljubljana, slovenia. exclusion criteria: * age below 18 years * relatives reported that patient died in the time since hospitalization * patient did not want a follow up * patient did not attend follow up appointment * patient underwent adrenalectomy * misdiagnosis / missing main information in hospitalization record

Keywords: adrenal incidentaloma bmi nfai mace long term follow up natural history
effect of eye movement desensitization and reprocessing therapy 2.0 online group protocol

Conditions: Post Traumatic Stress Disorder

Summary: in this study, it will be investigated the efficacy of eye movement desensitization and reprocessing therapy 2.0 online group protocol on post-traumatic symptoms compared to control group. therefore, the randomized control trial is based on eye movement desensitization and reprocessing therapy 2.0 group as an intervention.

eye movement desensitization and reprocessing therapy is an evidence-based psychotherapy approach, and it is proven as efficient in primarily post-traumatic symptom disorder. emdr 2.0 is a new approach which is used for the cases that are not answering the standard emdr protocols. according to the recent studies, both emdr and emdr 2.0 show a greater decrease in emotionality and vividness in similar time based on session numbers (matthijssen, 2021). also, it is found that emdr 2.0 requires lower set numbers (shorter sessions) compared to emdr. in this study, it will be investigated the efficacy of emdr 2.0 online group protocol on post-traumatic symptoms compared to control group. therefore, the randomized control trial is based on emdr 2.0 group as an intervention. compared to previous emdr 2.0 individual settings, this study is based on a group protocol made by our team. this group protocol has been tested in a pilot study on volunteer mental health professionals. the results of this pilot study showed that emdr 2.0 group protocol was successful, and investigators decided to begin the randomized control trial research.

Eligibility criteria:
inclusion criteria: * being older than 18 * having a traffic accident between 6 months and 10 years * having necessary knowledge on using relevant technological devices exclusion criteria: * having mental deterioration after the accident * having a lower score of 7 on adverse childhood experiences (aces) * having pre-existing psychotic disorder

Keywords: emdr post-traumatic stress disorder anxiety depression stress trauma
pilot study of bisphosphonate therapy (zoledronic acid) in patients with malignant mesothelioma (uab 0901)

Conditions: Mesothelioma

Summary: the primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the eortc modified recist criteria and the eortc tumor response criteria for 18f-fdg pet scans.

this pilot study will examine the effect of bisphosphonate (zoledronic acid) in patients with malignant mesothelioma. evaluation will be limited to patients with standard (ct scans) and functional instruments (fdg pet scans) of tumor assessment after the administration of standard doses of zoledronic acid (4 mg iv every 3 weeks). we will also explore the biologic effect of zoledronic acid in patients using new serum markers as well as several blood level markers.

Eligibility criteria:
inclusion criteria: * males and females \> 18 years of age * life expectancy of at least 2 months * histologically confirmed unresectable malignant pleural mesothelioma (mpm) * measurable disease by ct scan criteria and/or positive metabolic activity of 18f-fdg pet scan criteria at screening * ecog performance status of 0-2 * laboratory and clinical results within 2 weeks prior to day 1 must be as follows: 1. anc ≥ 1.5 x 109/l 2. platelet count ≥ 100 x 109/l 3. hemoglobin ≥ 9g/dl 4. serum bilirubin ≤ 1.5 x upper limit of normal (uln) 5. ast ≤ 2.5 x uln 6. alt ≤ 2.5 x uln 7. alk-p ≤ 3 x uln 8. serum creatinine ≤ 1.8mg/dl 9. calculated serum creatinine clearance 40 - \> 60ml/min * female subjects of childbearing potential and all male subjects must be surgically sterile or consent to use a medically acceptable method of contraception throughout the trial. * willing and able to provide written informed consent. exclusion criteria: * known central nervous system (cns) tumor involvement * evidence of other active malignancy requiring treatment * clinically significant heart disease (e.g., congestive heart failure of new york heart association class 3 or 4 angina not well controlled by medication, or myocardial infarction within 6 months) * known infection with hiv or hepatitis * clinically significant arrhythmias demonstrated on electrocardiogram (ecg). note: subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia (svt) are eligible. * active, serious systemic disease, including active bacterial or fungal infection. * subjects undergoing invasive dental procedures, significant periodontal disease or history of osteonecrosis of the jaw. * treatment within 4 weeks of the start of the trial with other systemic anticancer therapy. * breastfeeding, pregnant, or likely to become pregnant during the clinical trial.

Keywords: mesothelioma zoledronic acid zometa bisphosphonate therapy ct scan pet scan
brain oxygenation during prehospital anesthesia: an observational study

Conditions: Critically Ill; Major Trauma; Anesthesia; Emergencies

Summary: brain oxygenation of adult patients undergoing prehospital emergency anesthesia is monitored using noninvasive near-infrared spectroscopy. patients are afterwards interviewed to define neurological outcome to measure quality of life. the purpose of this study is to reveal the risk factors of prehospital anesthesia related cerebral desaturation events (cde) and to define the association between cde and survival, neurological outcome or quality of life.


Eligibility criteria:
inclusion criteria: * sedation or anesthesia provided to facilitate endotracheal intubation, performed by helicopter emergency medical services (hems) team regardless of the reason exclusion criteria: * ongoing cardiopulmonary resuscitation at the time of intubation * physical barrier for near-infrared spectroscopy measuring (e.g. forehead laceration) * hems unit does not escort patient to the hospital (exception: in case of death on scene after inclusion, patient is included) * workload too high to ensure standard level of clinical care during the study * for interviews: no competence in finnish, swedish or english
thalidomide plus dexamethasone as maintenance therapy for multiple myeloma

Conditions: Multiple Myeloma

Summary: this multicenter, prospective, randomized trial was designed to evaluate the role of thalidomide with or without dexamethasone as a maintenance therapy for multiple myeloma patients after a single autologous stem cell transplantation.

patients were recruited prior to receiving induction therapy, and randomization in a 1:1 ratio occurred on day 60 post-autologous stem cell transplantation. the treatment consisted of the following four phases: 1. induction with 3-5 cycles of vincristine plus doxorrubicin and dexamethasone (vad) every 21-28 days: vincristine 0.4 mg , doxorubicin 9 mg/m² and oral dexamethasone 40 mg daily for 4 days; 2. cyclophosphamide (4 g/m2 ) plus filgrastim (g-csf) (5 μg/kg twice a day) for stem cell mobilization; 3. melphalan (200 mg/m2 ) and one autologous stem cell transplant (asct); 4. sixty days (d +60) after asct: randomization in two arms of maintenance: arm a (oral dexamethasone alone 40 mg/d for 4 days every 28 days) and arm b (dexamethasone plus thalidomide 200 mg daily by mouth) for 12 months or until disease progression.

Eligibility criteria:
inclusion criteria: * symptomatic multiple myeloma in accordance with the international myeloma working group criteria; * age 18-70 years; * performance status 0-2 by the eastern cooperative oncology group (ecog) criteria; * normal hepatic function, defined as serum bilirubin \<3 mg/dl and alanine aminotransferase(alt) and asparagin aminotransferase (ast) \<4x normal. exclusion criteria: * evidence of disease progression after asct; * cardiac dysfunction (systolic ejection fraction \<50%); * chronic respiratory disease (carbon monoxide diffusion \<50% of normal).

Keywords: multiple myeloma treatment maintenance thalidomide
effects of low dose ketamine given at induction of anesthesia on postoperative mood in patients with depressive symptoms

Conditions: Depression; Major Depressive Disorder

Summary: ketamine has been shown to have an antidepressant effect when given intravenously in doses of 2mg/kg. ketamine is used as a standard induction drug during general anesthesia. it is known in this instance to decrease postoperative pain. no one has studied whether or not ketamine when given in doses used during general anesthesia (0.5mg/kg intravenous) has an antidepressant effect on surgical patients who suffer from depression. the study is designed to determine whether or not a small dose of ketamine when given at the induction of anesthesia could have an antidepressant effect on surgical patients with depression.

non-pregnant females between the ages of 18-65 who are being admitted for gynecological surgery will be given a bedside goldberg depression screen as part of their routine preanesthetic assessment. if the patient scores five or above on the goldberg depression screening, they will be asked if they would like to enroll in the study. exclusion criteria include uncontrolled hypertension, pregnancy, or allergy to ketamine. once the patient is consented they will be randomized to one of two groups. every patient will receive an antianxiety medication midazolam and a narcotic fentanyl prior to going to the operating room. group a will receive ketamine 0.5mg/kg intravenous as part of their induction for general anesthesia. group b will not receive ketamine as part of their anesthetic. all other induction drugs will be at the discretion of the anesthesiologist performing the anesthetic. the patients will be seen by a separate anesthesia provider (who is blinded to the group the patient is in) and the results of the depression screening will be added to the patient's data sheet. the patients will be followed again one week after their surgery either in their hospital room (if still hospitalized) or by phone. they will again be given the goldberg depression screen and the data will again be added to their data sheet. several times during the study and at its conclusion the data will be matched with the patients group in order to assess for adverse events such as suicidal ideations, nausea and vomiting. if adverse events are noted, the study design will be altered to take into account the adverse events.

Eligibility criteria:
inclusion criteria: * history of or current depression scoring five or above on goldberg depression screen exclusion criteria: * uncontrolled hypertension, allergy to ketamine,pregnancy

Keywords: depression gynecoligical surgery ketamine
sitagliptin in type i diabetic patients

Conditions: Diabetes Type I

Summary: the purpose of the study is to evaluate the effect of sitagliptin on overall blood glucose concentrations in type i diabetic subjects. the study also aims to evaluate post meal glucagon concentrations in type i diabetic subjects (a possible mechanism of reduced blood glucose concentrations) and indices of oxidation stress in the plasma of these subjects.

the hypothesis is that sitagliptin will improve overall blood glucose, fasting blood glucose, and glycemic excursions in patients with type i diabetes. in addition, sitagliptin will likely suppress indices of oxidative stress in patients. the study will investigate proposed mechanisms of improved glucose concentrations, including enhanced effect of endogenous glp-1 and suppression of glucagon.

Eligibility criteria:
inclusion criteria: 1. male or female adult, aged 18 to 70 years 2. type 1 diabetes mellitus for 6 months or more, as established by medical history 3. current treatment with multiple injections of insulin (at least 4) or csii (continuous subcutaneous insulin infusion or insulin pump) therapy for at least 3 months prior to screening visit; and using the same insulin during the last 1 month 4. hba1c ≤ 8.5% 5. subjects should routinely practice at least 2-4 blood glucose measurements per day 6. bmi ≤ 35 kg/m2 7. subject must be able and willing to perform self-blood glucose monitoring and accept wearing a continuous glucose monitor for 3 days at the start and 3 days at the end of the study 8. subjects must be willing to complete study visits per study protocol 9. able to speak, read, and write english exclusion criteria: 1. type 1 diabetes mellitus for less than 6 months 2. coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery, or coronary angioplasty) in the previous 4 weeks 3. any other life-threatening, non-cardiac disease 4. pregnant or intends to become pregnant during the course of the study 5. severe unexplained hypoglycemia that required emergency treatment over the past 3 months 6. history of hemoglobinopathies 7. post-renal transplantation, currently undergoing dialysis, creatinine of \>1.5mg/dl or a calculated creatinine clearance of \<50 ml/min. 8. have extensive skin changes/diseases that inhibit wearing the sensor on normal skin 9. subjects who have an allergy to medication being used 10. current participation in another study protocol 11. history of autonomic neuropathy or gastroparesis
kaiser permanente hiv cohort study

Conditions: HIV; AIDS

Summary: human immunodeficiency virus (hiv) infected patients in the kaiser permanente hiv registry wil be followed in the usual clinical care to estimate the rates of specified clinical events. the rates will be stratified by relevant characteristics like age, cd4 counts, hiv viral load (vl), hiv medication history. the rates in the hiv infected cohort wil be compared with the rates of these events in patients in the kaiser permanente database who are not infected with hiv.

all hiv infected patients in the database will be included without any sampling. a random sample of non-hiv infected patients will be included as comparator.

Eligibility criteria:
inclusion criteria: hiv infection. exclusion criteria: none
cosmetic products and facial skin microbiome

Conditions: Cosmetics Product Effects

Summary: the skin microbiome diversity in female healthy volunteers will be studied along with cosmetic products application in 1 month period. this study is also aimed to investigate the efficacy of cosmetic products on skin rejuvenation. .

the study is conducted in covid-19 pandemic era, thus every person involved in this study must follow health protocol for covid-19. the study procedure, consist of screening visit (d -7), 7-day wash out, baseline visit (d 0), first follow up ( d 14), and second follow up (d 28). 1. screening visit: obtained informed consent, covid-19 detection by swab rt-pcr, and inclusion and exclusion criteria, wash out product dispensing, and subject's diary dispensing. 2. baseline visit: investigator will check vital signs, facial skin value by cutometer, mexameter, sebumeter, corneometer, colorimeter, tewameter, dan ph meter, and kin taping by corneofix tape. investigational products will dispensed in this visit for 2 weeks usage. 3. first follow up: investigator will check vital signs and facial skin value. investigational products will dispensed in this visit for 2 weeks usage. 4. second follow up: investigator will check vital signs, facial skin value, and skin taping by corneofix tape. all adverse events (aes) occurred during study will be recorded in case report form.

Eligibility criteria:
inclusion criteria: 1. female 18-35 years old 2. signed the informed consent exclusion criteria: 1. infected by covid-19 2. females with skin diseases on face and neck such as atopic dermatitis, skin allergy, acne with moderate and severe degree, seborrheic dermatitis, malignancy 3. females with ongoing skin treatments.

Keywords: skin microbiome facial skin microbiome microbiome diversity
combined stn and nbm deep brain stimulation for mild cognitive impairment in parkinson's disease

Conditions: Parkinson's Disease; Mild Cognitive Impairment

Summary: the goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (dbs) of the subthalamic nucleus (stn) and nucleus basalis of meynert (nbm) to treat cognitive and cognitive-motor symptoms in individuals with parkinson's disease. the main question it aims to answer is: is a combined deep brain stimulation approach targeting the stn and nbm with four dbs leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with parkinson's disease with mild cognitive impairment. ten participants are anticipated to be enrolled. participants will undergo a modification of the traditional stn dbs approach for motor symptoms of pd. in addition to the two leads placed within the stn, two additional leads will be placed with the nbm for treatment of cognitive and cognitive-motor symptoms. novel stimulation patterns will be used within the nbm to target cognitive and cognitive-motor symptoms using an investigational software. participants will be followed over two years while receiving this therapy with assessments at baseline and every six months. assessments will include a combination of neuropsychological evaluations, cognitive assessments, motor tasks (including gait/walking), and questionnaires to evaluate the treatment. two different surgical trajectories will be used, with half the cohort randomized to each group. this will allow comparison of the impact of surgical trajectory on the intervention.


Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease (pd) * approved (or planning on) for subthalamic nucleus (stn) deep brain stimulation (dbs) * willingness to withdraw from clinical medication regimen when necessary for research visits * ability to provide informed consent exclusion criteria: * dementia * unstable medical, psychiatric conditions including significant untreated depression, history of suicidal attempt, or current suicide ideation * history of seizures * pregnant * requires mri * unable to walk 100 feet without an assistive device

Keywords: deep brain stimulation cognition dbs parkinson's disease